Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Transl Lung Cancer Res. 2016 Jun;5(3):239-43. doi: 10.21037/tlcr.2016.05.03.
Concurrent chemoradiation (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (NSCLC) with a modest survival benefit over sequential chemoradiation or radiotherapy (SCRT) alone. However, this benefit is at the cost of increasing acute toxicity such as esophagitis. Previous analysis revealed several predictive parameters in dose-volume and patient characteristics which helped us to identify those patients at risk for severe esophagus toxicity. As a result, supportive care interventions including individualized patient information, dietary guidance, adequate medication, hydration and tubefeeding could be initiated. This paper discusses the challenges in overcoming chemoradiation induced acute esophageal toxicity (AET).
同期放化疗(CCRT)是局部晚期非小细胞肺癌(NSCLC)的治疗选择,与序贯放化疗或单纯放疗(SCRT)相比,具有适度的生存获益。然而,这种获益是以增加急性毒性(如食管炎)为代价的。先前的分析显示了剂量-体积和患者特征中的几个预测参数,这些参数帮助我们识别了那些有严重食管毒性风险的患者。因此,可以开始实施支持性护理干预措施,包括个体化的患者信息、饮食指导、充足的药物、水合作用和管饲。本文讨论了克服放化疗引起的急性食管毒性(AET)的挑战。